HighLight Capital

HighLight Capital is a private equity firm dedicated to supporting healthcare companies in China, aiming to foster robust and sustained growth in the sector. The firm focuses on various healthcare-related industries, including biotechnology, medical devices, pharmaceuticals, and consumer health. HighLight Capital's investment approach is characterized by a pragmatic and diversified value investment methodology, driven by specialized fundamental industry research and independent analysis. The firm emphasizes core values such as inspiration, passion, value, creativity, compassion, and kindness in its operations.

In September 2022, HighLight Capital achieved a first close of USD 540 million on its fourth US dollar-denominated fund, targeting a total of USD 650 million. This fund focuses on life sciences investments, underscoring the firm's commitment to the healthcare sector. The firm's assets under management (AUM) have grown to over USD 3.8 billion, reflecting its expanding presence in the market. HighLight Capital has a track record of successful investments, including leading a USD 72 million Series D funding round for Chinese medical devices manufacturer Hanyu Medical in August 2020.

HighLight Capital's portfolio includes companies such as GenFleet, which completed its initial public offering on the Hong Kong Stock Exchange in September 2025, and Ab&B Bio-Tech, which made a record-breaking debut on the Hong Kong Stock Exchange in August 2025. These investments highlight the firm's focus on partnering with entrepreneurs who demonstrate dedication and uphold high standards, aiming to build a world-class health-focused investment platform to foster great healthcare and wellness enterprises in China.